![](/images/graphics-bg.png)
Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management
المؤلفون المشاركون
Lomax, Anna J.
Lim, Jennifer
Cheng, Robert
Sweeting, Arianne
Lowe, Patricia
McGill, Neil
Shackel, Nicholas
McNeil, Catriona
Chua, Elizabeth
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-13، 13ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-01-21
دولة النشر
مصر
عدد الصفحات
13
التخصصات الرئيسية
الملخص EN
Immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) are a standard of care for advanced melanoma.
Novel toxicities comprise immune-related adverse events (irAE).
With increasing use, irAE require recognition, practical management strategies, and multidisciplinary care.
We retrospectively evaluated the incidence, kinetics, and management of irAE in 41 patients receiving anti-PD-1 antibody therapy (pembrolizumab) for advanced melanoma.
63% received prior anti-CTLA-4 antibody therapy (ipilimumab).
IrAE occurred in 54%, most commonly dermatological (24%), rheumatological (22%), and thyroid dysfunction (12%).
Thyroiditis was characterised by a brief asymptomatic hyperthyroid phase followed by a symptomatic hypothyroid phase requiring thyroxine replacement.
Transplant rejection doses of methylprednisolone were necessary to manage refractory hepatotoxicity.
A bullous pemphigoid-like skin reaction with refractory pruritus responded to corticosteroids and neuropathic analgesia.
Disabling grade 3-4 oligoarthritis required sulfasalazine therapy in combination with steroids.
The median interval between the last dose of anti-CTLA-4 antibody and the first dose of anti-PD-1 therapy was 2.0 months (range: 0.4 to 22.4).
Toxicities may occur late; this requires vigilance and multidisciplinary management which may allow effective anticancer therapy to continue.
Management algorithms for thyroiditis, hypophysitis, arthralgia/arthritis, colitis, steroid-refractory hepatitis, and skin toxicity are discussed.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Lomax, Anna J.& Lim, Jennifer& Cheng, Robert& Sweeting, Arianne& Lowe, Patricia& McGill, Neil…[et al.]. 2018. Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. Journal of Skin Cancer،Vol. 2018, no. 2018, pp.1-13.
https://search.emarefa.net/detail/BIM-1202353
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Lomax, Anna J.…[et al.]. Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. Journal of Skin Cancer No. 2018 (2018), pp.1-13.
https://search.emarefa.net/detail/BIM-1202353
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Lomax, Anna J.& Lim, Jennifer& Cheng, Robert& Sweeting, Arianne& Lowe, Patricia& McGill, Neil…[et al.]. Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. Journal of Skin Cancer. 2018. Vol. 2018, no. 2018, pp.1-13.
https://search.emarefa.net/detail/BIM-1202353
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1202353
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)